Global Duchenne Muscular Dystrophy Therapeutics Market Overview
Duchenne Muscular Dystrophy (DMD) is the serious type of muscle diseases that affects the male population at the age of four and make them lose their ability to walk by 12. Due to its rare effects, it is termed as orphan diseases and can be found for approximately 1 in 3,500 male population. Compared to the previous decade, several new treatment methods have been developed recently to detect and treat the diseases, which is collectively known as Duchenne muscular dystrophy (DMD) therapeutics.
Factors Driving the Growth of Global Duchenne Muscular Dystrophy Therapeutics Market:
The average life expectancy of the children affected by this muscular dystrophy is 26 years, however, it can be extended to 30 years or 40 years with regular medical care. The general symptoms of this disease include weakness in muscles of the hips, pelvic area, thighs, shoulders, arms, legs, and trunk. Although there is no cure for this diseases, new therapeutics have been developed to control its progression in the body. Molecular-based therapies like mutation suppression or exon skipping are the most common treatments for the Duchenne Muscular Dystrophy (DMD).
There are some significant factors driving the global Duchenne Muscular Dystrophy (DMD) therapeutics market such as the increasing development of new drugs, rise in the research and development, growing demand for the therapeutics among the patients, mounting cases of other chronic diseases cardiovascular, neurovascular, and arthritis, increasing availability health insurance, growth in the health care spending of the people, and so on. However, the delayed process for the prognosis is the major restraining aspect of the market expansion.
Browse details of 80 pages research report developed on GlobalDuchenne Muscular Dystrophy Market @ https://www.researchcosmos.com/reports/global-duchenne-muscular-dystrophy-therapeutics-market-outlo/4958600
Based on the geography, North America accounts for the largest share of the global Duchenne Muscular Dystrophy therapeutics market due to the launch of innovative products, healthcare expenditure, investments in the research and development, and government supportive initiatives. Europe is next in line to North America, and the Asia Pacific region is expected to register higher growth rate in the future.
Some of the Leading Companies in the Global Duchenne Muscular Dystrophy Therapeutics Market:
Some of the leading contributors to the global Duchenne Muscular Dystrophy therapeutics market are Eli Lilly and Company, Pfizer, Inc., Santhera Pharmaceuticals Holding, Nobelpharma Co., Ltd., Sarepta Therapeutics, Inc., Tivorsan Pharmaceuticals, Acceleron Pharma, Inc., Asklepios Kliniken GmbH, FibroGen, Inc., and BioMarin Pharmaceutical, Inc.
Research Cosmos is a provider of standard and customized market research, business intelligence and consulting services across more than 100 domains in different industries of the world. We host the trending market reports of the world’s top-notch publishing companies, offering services to a wide range of customers from students to fortune 500 companies and discloses the hidden opportunities in every leading industry of the world.
Global Sales Manager
+1 888 709 8757